Resumen de acción MCK
McKesson Corporation presta servicios sanitarios en Estados Unidos y a escala internacional.
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 2/6 |
| Salud financiera | 2/6 |
| Dividendos | 0/6 |
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
WA
Based on Analyst Price Targets
Leveraging AI And Decisive Partnerships Boosts Growth In Oncology And Biopharma, Outpacing Market Challenges
US$584.00
FV
12.8% undervalued intrinsic discount10.01%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
4 days ago author updated this narrative
Competidores de McKesson Corporation
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$509.20 |
| Máximo en las últimas 52 semanas | US$637.51 |
| Mínimo de 52 semanas | US$431.35 |
| Beta | 0.43 |
| 1Cambio en 1 mes | 0.24% |
| Variación en 3 meses | -12.66% |
| Cambio de 1 año | 12.45% |
| 3Variación en 3 años | 143.53% |
| Variación en 5 años | 248.86% |
| Variación desde la OPV | 2,986.06% |
Noticias y actualizaciones recientes
McKesson Corporation: A Defensive Healthcare Value Stock Without A Patent Cliff
Oct 09McKesson: The Correction Is Not Over
Sep 10Recent updates
McKesson Corporation: A Defensive Healthcare Value Stock Without A Patent Cliff
Oct 09McKesson: The Correction Is Not Over
Sep 10McKesson Corporation (NYSE:MCK) Not Lagging Market On Growth Or Pricing
Aug 22
McKesson Corporation: An Interesting Health Giant With A Hidden Gem
Jul 04With McKesson Corporation (NYSE:MCK) It Looks Like You'll Get What You Pay For
May 09Is McKesson Corporation (NYSE:MCK) Trading At A 43% Discount?
Mar 14McKesson: GLP-1 Contributed More Than 1/3 Of Growth
Feb 19McKesson's (NYSE:MCK) Profits May Not Reveal Underlying Issues
Feb 16Investor Optimism Abounds McKesson Corporation (NYSE:MCK) But Growth Is Lacking
Jan 29McKesson: Why The Company Is Too Richly Valued
Jan 19If EPS Growth Is Important To You, McKesson (NYSE:MCK) Presents An Opportunity
Nov 20McKesson: GLP-1 Medications Tailwinds And Massive Share Repurchase
Nov 08Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 44%?
Oct 30McKesson: Still Trading For A Huge Discount
Sep 06Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors
Aug 21Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 29%?
Jul 27McKesson: Outlook Remains Positive, I Reiterate My Buy Recommendation
Jun 28Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors
May 23Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 32%?
Apr 17Do McKesson's (NYSE:MCK) Earnings Warrant Your Attention?
Feb 22McKesson Corporation: Looking Forward To Long-Term Low-Teens EPS Growth
Feb 08McKesson Non-GAAP EPS of $6.90 beats by $0.54, revenue of $70.5B misses by $480M
Feb 01McKesson Corporation's (NYSE:MCK) Intrinsic Value Is Potentially 33% Above Its Share Price
Jan 125 Reasons Why I Am Considering Adding McKesson To My Portfolio
Dec 27McKesson Corporation: Still Trading Below Intrinsic Value
Dec 13Duration: The Time Bomb In Your Portfolio - McKesson And PayPal In Focus
Oct 08McKesson extends distribution partnership with CVS Health
Sep 29An Intrinsic Calculation For McKesson Corporation (NYSE:MCK) Suggests It's 50% Undervalued
Sep 19Rentabilidad de los accionistas
| MCK | US Healthcare | Mercado US | |
|---|---|---|---|
| 7D | 0.7% | -4.3% | 0.8% |
| 1Y | 12.5% | 4.2% | 38.4% |
Rentabilidad vs. Industria: MCK superó a la industria US Healthcare, que obtuvo un rendimiento del 7.9% el año pasado.
Rentabilidad vs. Mercado: MCK obtuvo unos resultados inferiores a los del mercado US, que fueron del 24.4% el año pasado.
Volatilidad de los precios
| MCK volatility | |
|---|---|
| MCK Average Weekly Movement | 5.0% |
| Healthcare Industry Average Movement | 6.9% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: MCK no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de MCK (2%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1833 | 48,000 | Brian Tyler | www.mckesson.com |
McKesson Corporation presta servicios sanitarios en Estados Unidos y a escala internacional. Opera a través de cuatro segmentos: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions e Internacional.
Resumen de fundamentos de McKesson Corporation
| Estadísticas fundamentales de MCK | |
|---|---|
| Capitalización bursátil | US$66.03b |
| Beneficios(TTM) | US$2.96b |
| Ingresos (TTM) | US$313.75b |
22.3x
Ratio precio-beneficio (PE)0.2x
Ratio precio-ventas (PS)¿Está MCK sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de MCK | |
|---|---|
| Ingresos | US$313.75b |
| Coste de los ingresos | US$301.04b |
| Beneficio bruto | US$12.71b |
| Otros gastos | US$9.76b |
| Beneficios | US$2.96b |
Últimos beneficios comunicados
Jun 30, 2024
Próxima fecha de beneficios
Nov 06, 2024
| Beneficios por acción (BPA) | 22.82 |
| Margen bruto | 4.05% |
| Margen de beneficio neto | 0.94% |
| Ratio deuda/patrimonio | -394.1% |
¿Cómo se ha desempeñado MCK a largo plazo?
Ver rendimiento histórico y comparativa